The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
General Updates | REALISM UK: current treatment pathways for myelofibrosis in the UK
Ciro Rinaldi, MD, PhD, Lincoln County Hospital, Lincoln, UK, gives an overview of the findings of the REALISM UK study which reviewed current treatment practices in myelofibrosis (MF) across the UK. Overall, although the study reported that there was a good application of the current clinical guidelines, it was found that in some centers, patients remained on a watch and wait management strategy for too long before switching to treatment with a JAK2 inhibitor, highlighting the need for better training in MPN management. This interview took place virtually.
